EQAs

GenQA provides a wide range of genomic external quality assessments (EQAs) for both laboratory based services, clinical genetics centres and individual assessment
Full details of all EQAs availabe can be accessed by clicking on the relevant links below.  

All EQAs scheduled for release during April, May and June 2020 are now POSTPONED.

Last updated: Thursday, 02 April 2020

2020-21 Colorectal cancer - core

Molecular testing of colorectal cancer. KRAS, NRAS and BRAF testing.

2020-21 Colorectal cancer - Extended MMR

Molecular testing of colorectal cancer. KRAS, NRAS, BRAF, MSI and MLH1 promoter methylation testing.

2020-21 Colorectal cancer - MMR

Molecular testing of colorectal cancer. KRAS, NRAS, BRAF and MLH1 promoter methylation testing.

2020-21 Lung cancer - comprehensive

Molecular testing of lung cancer. EGFR, ALK, ROS1, BRAF, KRAS, MET, RET, PIK3CA testing.

2020-21 Lung cancer - core

Molecular testing of lung cancer. EGFR, ALK, ROS1

2020-21 Lung cancer - EGFR only

Molecular testing of lung cancer - testing of EGFR only.

2020-21 Lung cancer - fusions

Molecular testing of lung cancer. ALK, ROS1, MET and RET

2020-21 MCADD blood spot

Molecular testing of newborn screening cards for ACADM variants, including c.985A>G p.(Lys329Glu), to determine their heterozygous/homozyous state.

2020-21 Melanoma

Molecular testing of Melanoma.

2020-21 SCID blood spot (pilot)

Molecular testing of newborn screening cards for TREC levels associated with Severe Combined Immunodeficiency (SCID).

Pages

Go to top